[Edaily Starin Gim Ga Yeong Reporter] Actress Kwak Sun-young has signed an exclusive contract with Prain TPC. Photo: Kwak Sun-youngOn the 20th, Prain TPC announced, “We have signed an exclusive contract with actress Kwak Sun-young, who has left a deep impression with her authentic acting,” adding, “We plan to spare no effort in supporting her so she can continue her activities across a wider range of genres and productions.” The agency continued, “We ask for your continued interest and warm support for the diverse projects Kwak Sun-young will undertake in the future.” Kwak Sun-young debuted in 2006 with *Dalgona* and has since appeared in numerous musicals, including *The Great Catsby*, *Notre-Dame de Paris*, *Finding Kim Jong-wook*, *Laundry*, and *In Praise of Death*. She subsequently expanded her reach into other media, starting with the drama *Dear Judge*, and gained widespread recognition through appearances in *Boyfriend*, *VIP*, *Gugyeong-i*, *Surviving as a Celebrity Manager*, *Hospital Playlist*, *Crash*, and *Moving*. In the ENA Monday-Tuesday drama *The Scarecrow*, which concluded last May, she played the role of Seo Ji-won, a reporter for the Gangseong Ilbo who considers it her mission to document the truth and bring it to the public’s attention. Meanwhile, Prain TPC represents Kwak Min-kyu, Kim Mu-yeol, Kim Beom-soo, Kim Shin-bi, Kim Hyun-joon, Ryu Seung-ryong, Park Yong-woo, Park Ji-young, Park Jin-ju, Park Hyung-soo, Bae Yoon-kyung, Baek Hyun-jin, Oh Yeon-ah, Oh Jung-se, Won Hyun-jun, Yoo Da-in, Yoon Seung-ah, Lee Kyu-sung, Lee So-hee, Lee Joon, Jo Eun-ji, Choi Myung-bin, and Ha Seo-yoon.
The way global private equity fund (PEF) managers invest in rental housing is evolving. Previously, most cases involved directly purchasing individual properties. However, transactions have recently e…
SK hynix has drawn a clear line regarding reports that it is pursuing the sale of its stake in its Chongqing, China, plant, stating, “Nothing has been finalized.” This is the company’s response to a r…
Medy-Tox Inc.(086900)Medytox continued its revenue growth in the second quarter of this year, driven by expanded overseas sales of botulinum toxin and dermal fillers, as well as the successful market …